There was no difference observed in the percentage of CD8+ T cell responders in patients with tumours with or without estrogen receptor expression, progesterone receptor, or triple-negative breast cancer or metastasis (data not shown). This evidence concerns the gene ESR1 and triple-negative breast carcinoma.